Antibody Responses to the SARS-CoV-2 Vaccines in Hemodialysis Patients: Is inactivated vaccine effective?


Posted: 2021-11-06 19:00:00
Introduction: Vaccines generally have reduced effectiveness in hemodialysis patients and a similar condition may also apply for the SARS-CoV-2 vaccines. The aim of this study was to analyze humoral responses of hemodialysis patients to SARS-CoV-2 vaccines. Methods: Eighty-five maintenance hemodialysis patients who received either inactivated or mRNA SARS-CoV-2 vaccines were investigated. Antibody levels were measured by a commercial antibody kit, which detected antibodies towards receptor binding domain of the SARS-CoV-2 spike protein. Comparative analyzes were carried between vaccine groups and with a control group of 103 healthy volunteers. Results: Seropositivity rate and antibody levels were significantly lower in hemodialysis patients who received inactivated vaccine (p=0,000). While mRNA vaccine had better immunogenicity, both vaccines protected from symptomatic infection when seropositivity was achieved. Discussion/conclusions: When used in the same dose with the general population, inactivated SARS-CoV-2 vaccines generate reduced humoral response in hemodialysis patients. mRNA vaccines have better immunogenicity in this group. This article is protected by copyright. All rights reserved. Keywords: COVID-19; SARS-CoV-2; hemodialysis; immunization; vaccine.

参考サイト PubMed: covid-19


Powered by Kreditvergleich


バイオクイックニュース日本語版:COVID-19特集

ゲスト 568人 と メンバー 2人 がオンラインです